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Abstract
Clinical trials on novel drug therapies require clear criteria for patient selection and agreed
definitions of disease remission. This principle has been successfully applied in the field of
rheumatology where agreed disease scoring systems have allowed multi-centre collaborations and
facilitated audit across treatment centres. Unfortunately in ulcerative colitis this consensus is
lacking. Thirteen scoring systems have been developed but none have been properly validated.
Most trials choose different endpoints and activity indices, making comparison of results from
different trials extremely difficult. International consensus on endoscopic, clinical and histological
scoring systems is essential as these are the key components used to determine entry criteria and
outcome measurements in clinical trials on ulcerative colitis. With multiple new therapies under
development, there is a pressing need for consensus to be reached.
Background
Clinical trials determining the efficacy of new treatments
need internationally agreed standardised endpoints. Only
these allow studies to be compared and, importantly,
combined for greater statistical power and a more reliable
estimate of the benefits and harms of an intervention.
Agreement on endpoints has been achieved for trials in
rheumatology (Outcome Measures in Rheumatology,
OMERACT [1]. OMERACT's consensual approach has
been extremely successful and we feel that this approach
now needs to be applied to trials of inflammatory bowel
disease.
In the field of gastroenterology there are many exciting
new drugs in development, with great prospects for the
treatment of ulcerative colitis in particular. International
consensus on the endoscopic, clinical and histological
scoring systems is essential as these are the key compo-
nents used to determine entry criteria and outcome meas-
urements in clinical trials of ulcerative colitis. As the aim
of all clinical trials is to determine whether an interven-
tion results in clinical response and/or remission, with an
acceptable adverse event profile, an agreed definition of
these parameters is paramount. Whereas in rheumatology
joint space narrowing may be measured with simple radi-
ography, in inflammatory bowel disease direct measures
are more difficult and often involve endoscopy. In this
paper we discuss the systems currently available and their
limitations. We propose potential solutions, focussing in
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particular on the issue of interobserver variation in sig-
moidoscopy.
Clinical scores
The multiplicity of clinical activity indices used for scoring
ulcerative colitis has recently been comprehensively
reviewed [2]. No less than seven different symptom-based
activity scores, two composite scores, and four evaluation
scoring systems have been used in ulcerative colitis [3-16]
[Table 1]. The names of the indices also vary between dif-
ferent publications which exacerbates the confusion
[Table 2]. The scores vary in the use of objective measure-
ments (stool frequency, temperature, pulse rate, results of
blood tests), subjective components (physician's global
assessment, general well being), and sigmoidoscopy,
which is itself open to wide inter-observer variation [Table
3].
In 1955 Truelove and Witts [3] were the first to attempt to
quantify disease activity defining mild, moderate and
severe disease. Endoscopy was added into a continuous
scale developed by Powell-Tuck and colleagues [4]. In the
early 1980s the eleven components of this index were sim-
plified in the Mayo score [5] and the Ulcerative Colitis
Disease Activity Index (UCDAI or Sutherland Index) [6],
which have three clinical variables and an endoscopy
score. Later, Rachmilewitz proposed the Clinical Activity
Index (CAI) which includes laboratory data as well as clin-
ical and endoscopic variables [7]. Other non-invasive
indices have been developed including the Seo index [9]
which measures symptoms and some simple laboratory
values (haemoglobin, erythrocyte sedimentation rate and
albumin) and the simple clinical colitis activity index
(SCCAI) [10] which has six clinical questions only. How-
ever, none of these scoring systems has been validated
with a formal evaluation of their biometric properties
(responsiveness, reliability and validity) [17].
Scoring systems for ulcerative colitis are driven by the
need to select appropriate patients and monitor response
in clinical trials, which is why interest waxes in time with
drug development (steroids in the 1950s, sulfasalazine in
the next two decades, mesalazine in the 1980s and
ciclosporin in the 1990s). Now, in 2007, there are up to
30 new agents being evaluated for the treatment of ulcer-
ative colitis in phase 2 and 3 trials [18], and there has been
a resurgence of interest in scoring systems. Yet only one
system (Truelove and Witts' [3]) is simple and objective
enough to use in clinical practice, as well as aiding clinical
decision making, but this score suffers from a lack of
responsiveness to changes in symptoms following an
intervention. Consequently the Food and Drug Adminis-
tration (FDA) currently favours the Mayo score, or Disease
Activity Index (DAI) [5], for trial design in ulcerative coli-
tis, although it is not yet completely wedded to this. This
brings arbitrary uniformity, but fails to bring objectivity,
because the Mayo scoring system includes the highly sub-
jective 'physician's global assessment'. Furthermore, the
score includes a sigmoidoscopy subscore which is itself
subjective, contributing additional variability and lack of
Table 1: Summary of activity indices used for ulcerative colitis
Index Year Also known as References
Clinical/biomedical
Truelove &Witts' 1955 3
Powell Tuck 1978 St Mark's Index 4
Rachmilewitz 1988 Clinical Activity Index (CAI) 7
Lichtiger 1990 Modified Truelove &Witts' Severity Index 8
Seo 1992 Activity index (AI) 9
Walmsley 1998 Simple Clinical Colitis Index (SCCAI) 10
Feagan 2005 Ulcerative Colitis Clinical Score (UCCS) 14
Composite (clinical and endoscopic)
Schroeder 1987 Mayo score, Disease Activity Index (DAI) 5
Sutherland 1987 Ulcerative Colitis Disease Activity Index (UCDAI) 6
Evaluation
Physician's Global Evaluation 1993 PGA 11
Investigator's Global Evaluation 1998 12
Individual Symptom Score 2002 13
Patient Defined Remission 2005 19
Quality of life
Inflammatory Bowel Disease Questionnaire IBDQ 15
Short-form 36 SF36 39T
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Table 2: Summary of different properties measured in clinical activity indices
Author and name of index
Truelove &Witts [3] Powell-Tuck [4] Schroeder [5] Rachmilewitz [7] Lichtiger [8] Seo [9] Walmsley [10]
Property St Mark's index Mayo score, Disease 
Activity Index (DAI)
Clinical Activity Index 
(CAI)
Modified Truelove &Witts' 
Severity Index (MTWSI)
Activity Index Simple Clinical 
Colitis Index 
(SCCAI)
Score range Mild, Moderate, Severe 0–24 0–12 0–23 0–21 70–300 0–20
Bowel frequency/24 hrs <4 (mild) >6 (severe) 0–2 (<3 to >6) 0–3 (normal to ≥ 5 
above normal)
0–3(<18 to >60/week) 0–4 (≤ 2 to ≥ 10) add total number/24 
hr × 13
0–3(day) 
1–2(night)
Stool form 0–2 Need for antidiarrhoeal 
agents
Urgency Faecal incontinence 0 or 1 0–3
Blood 0–2 0–3 0–4 0–3 add bloody stools/24 
hr × 60
0–3
Abdominal Pain 0–2 0–3 0–3 0–4
Abdominal tenderness 0–4
General well-being 0–3 0–3 0–5 0–4
Anorexia 0–1
Nausea/Vomiting 0–1
Extra-intestinal features 0–3 0–9 0–5
Fever >37.5°C (severe) 0 – 2 (<37.1 to >38°C) 0 (<38°C) or 3 (>38°C)
Tachycardia >90
Anaemia <75% of normal 0 or 4 subtract value × 4
ESR mm/hr >30 0–2 add value × 0.5
Albumin subtract value × 15
Sigmoidoscopy 0–2 0–3 0–12
Global assessment 0–3 0–3 0–5 Score = sum of the 
above and add 200
Note: precise details of the individual components of each score are too complex to be included in a single table: refer to original article or ref [2]Trials 2007, 8:17 http://www.trialsjournal.com/content/8/1/17
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precision. Also, the physician's global assessment takes
into account the sigmoidoscopy score and is therefore not
independent of the other elements.
There is in fact no reason to combine clinical, sigmoidos-
copy, histopathology and quality of life variables into a
single index. Indeed there is a strong argument against
this. It is much easier to validate separate scoring systems
for each component. Clinical trials can then be based on
four validated scores, at least two of which (histology and
quality of life) would usually be secondary endpoints.
Indeed, even endoscopic mucosal healing could be a sec-
ondary endpoint, since this represents a tiny component
(<1%) of complete remission, compared to subjective
clinical remission recognised by the patient [19]. These
endpoints remain, however, important to measure
because they may influence long term outcome measures,
such as the potential link between inflammation and car-
cinogenesis.
Despite careful evaluation of the strengths and weak-
nesses of all of these indices in the review of activity indi-
ces by authors from the International Organisation for
Inflammatory Bowel Disease (IOIBD) [2], there is no
escaping the fact that there has been no validation, nor
any determination of inter-observer variability in scoring
between indices. This has to be done. It is otherwise
impossible to determine which index shows greatest con-
sistency between observers, which matters enormously
when investigators from four continents are recruiting
patients to the same clinical trial. A practical example of
the dilemma that this presents was the finding in 2006
that patients admitted from Russian centres to a clinical
trial of a p38 MAP kinase inhibitor had significantly
Table 3: Endoscopic scores for ulcerative colitis
S c o r e  [ r e f ] 01234
Baron [ 21] Normal: matt mucosa, 
ramifying vascular 
patter clearly visible, 
no spontaneous 
bleeding, no bleeding 
to light touch
Abnormal, but non-
haemorrhagic: 
appearances between 
0 and 2
Moderately 
haemorrhagic: 
bleeding to light 
touch, but no 
spontaneous bleeding 
seen ahead of the 
instrument on initial 
inspection
Severely 
haemorrhagic: 
spontaneous bleeding 
seen ahead of 
instrument at initial 
inspection and bleeds 
to light touch
-
Powell-Tuck [4] Non-haemorrhagic 
(no bleeding 
spontaneously or on 
light touch)
Haemorrhagic 
(bleeding on light 
touch, but no 
spontaneous bleeding 
ahead of instrument)
Haemorrhagic 
(spontaneous bleeding 
seen ahead of 
instrument on initial 
inspection and 
bleeding to light 
touch)
--
Rachmilewitz [7] No granulation 
scattering light, 
normal vascular 
pattern, no mucosal 
vulnerability, no 
mucosal damage 
(mucus, fibrin, 
exudates, ulcer)
Faded or disturbed 
vascular pattern
Granulation scattering 
light, completely 
absent vascular 
pattern, contact 
bleeding, slight 
mucosal damage
Spontaneous 
bleeding,, pronounced 
mucosal damage
-
Lémann [16] Normal mucosa Oedema and/or loss 
of mucosal vascularity, 
granularity
Friability (visible, 
induced bleeding on 
examination), 
petechiae
Spontaneous 
haemorrhage, visible 
ulcers
-
Schroeder [5] Normal or inactive 
disease
Mild (erythema, 
decreased vascular 
pattern, mild friability)
Moderate (marked 
erythema, absent 
vascular pattern, 
friability, erosions)
Severe (spontaneous 
bleeding, ulceration)
-
Sutherland [6] Normal Mild friability Moderate friability Exudation, 
spontaneous 
haemorrhage
-
Feagan [14] Normal, smooth, 
glistening mucosa, 
with vascular pattern 
visible; not friable
Granular mucosa; 
vascular pattern not 
visible; not friable; 
hyperaemia
As 1, with a friable 
mucosa, but not 
spontaneously 
bleeding
As 2, but mucosa 
spontaneously 
bleeding
As 3, but clear 
ulceration; denuded 
mucosaTrials 2007, 8:17 http://www.trialsjournal.com/content/8/1/17
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higher remission and response rates than non-Russian
centres [20].
Endoscopic scores
The general endoscopic grading system for ulcerative col-
itis was defined more than forty years ago by Baron et al
[21]. It has been used in all trials of active ulcerative colitis
to this day, with only minor (and unvalidated) modifica-
tion [5]. The durability of this scoring system is astonish-
ing; especially when it is considered that it was derived
form observations made by 3 observers in 60 patients
using rigid sigmoidoscopy. Nevertheless, the description
and assessment of each component (compared to the
unvalidated terms used by other indices, Table 3) means
that it has largely stood the test of time. Four grades are
defined (0–3) by the Baron score according to the severity
of macroscopic inflammation of the rectal mucosal
appearances at rigid sigmoidoscopy [Table 3]. The score
has not been validated using flexible sigmoidoscopy and
higher resolution endoscopes. Seven other endoscopic
scoring systems have since been proposed, but none has
gained similar acceptance [2].
Baron and two colleagues identified 14 visible variables
that they scored and compared between observers [Table
4]. There was 40% disagreement on grading appearances
as normal, mild, moderate, or severe activity. Not surpris-
ingly, binary variables (present or absent) were associated
with greater inter-observer agreement than graded varia-
bles. Unfortunately kappa scores are not available as the
paper was written before the kappa statistic was widely
applied to clinical medicine [22]. One variable, mucosal
friability was pivotal in discriminating between mild and
moderately active ulcerative colitis. This has acquired
immediate clinical relevance now that common therapy
has been shown to work for moderately active, but not
mild, ulcerative colitis [23]. Friability in Baron's time was
evaluated by wiping the mucosa with a cotton wool
pledget on biopsy forceps or 'rocket swab' and seeing
whether this provoked mucosal bleeding. The pressure
needed and techniques were never defined, nor has this
technique been validated in the era of flexible sigmoidos-
copy when cotton wool pledges and rocket swabs are
obsolete. Nevertheless, mucosal friability assessed at flex-
ible sigmoidoscopy remains the pivotal discriminator not
only for entry into clinical trials, but also for determining
outcome. Patients who have no mucosal friability (Baron
= 1 or 0) at outcome are deemed to have responded, as
long as the mucosal friability (Baron = 2 or 3) was present
at trial entry.
Despite grading the severity of the appearance, the criteria
did not claim any relation to disease severity. Baron et al
observed that 'No attempt has been made to correlate
these appearances with the clinical course or histological
appearances' [21]. Remarkably, after 40 years, the score
has still not been validated against clinical symptoms or
histopathology of biopsy specimens. Nor has it been vali-
dated against outcome, although attempts have been
made to correlate symptomatic (clinical) activity and
endoscopic appearance (below). Furthermore, despite
wide inter-observer variation and the pivotal role of
endoscopy in clinical trials of ulcerative colitis [2,23-26],
there has also been no attempt to determine intra-
observer variation of scores using flexible sigmoidoscopy
and digital imaging records viewed by the same observer
on different occasions.
Remission in ulcerative colitis
As if controversy about measuring disease activity was not
enough, even disease remission has been neither defined
nor validated. Remission is the outcome that matters in
clinical trials, so agreement on the definition of remission
is essential. Defining remission should logically be the
starting point of agreeing how to measure activity in ulcer-
ative colitis.
There are, however, at least three definitions of remission
for ulcerative colitis. These may be termed clinical, regis-
tration and complete remission [Table 5]. Clinical remis-
sion is what is used in everyday clinical practice, meaning
cessation of rectal bleeding and a normal stool frequency.
This is not the same as 'registration' remission (the one
currently, but not exclusively favoured by the FDA), which
means cessation of rectal bleeding and a sigmoidoscopy
score of 0 or 1 (equivalent to a normal appearance of the
rectal mucosa, or erythema only [Table 3]). This, in turn is
Table 4: Visible variables at sigmoidoscopy [21]
Visible variable Agreement 
(3 observers)
• Spontaneous bleeding (present or absent)
• Friability = 'bleeding to light touch' (present or 
absent)
• Moisture (normal 'dry', moist, 'oedematous')
• Distensibility (normal, rigid/contracted) >60%
• Valves (normal sharp crescent folds, swollen, 
absent)
• Large deep vessels (visible, not seen)
• Ulcers (present or absent*)
• Polyp (present or absent*)
• Granularity (normal smoothness, granular)
• Mucosal surface (attempt to describe the sheen on 
the mucosa: normal mat, dull lustreless; wet shiny)
<60%
• Colour (red, pink, pale)
• Mucopus (no mucus or pus, clear mucus, opaque 
pus)
• Faeces (none, solid, liquid)
Small superficial vessels (normal, few, patchy)
*:100% agreement, because none seenTrials 2007, 8:17 http://www.trialsjournal.com/content/8/1/17
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not the same as complete remission, which implies nor-
mal stool frequency, no rectal bleeding and a normal or
quiescent appearances of the mucosa at sigmoidoscopy.
The potential impact of these three definitions is consid-
erable, but many trials simply use an arbitrary threshold
to define the 'remission' endpoint. This is either 0, 1 or 2
of one of the disease activity indices, or <150 in the com-
plex Seo index [2]. This variation makes it difficult to
know what a trial means, because obscured in these low
scores can be symptoms (such as bleeding or increased
stool frequency) that clinicians and their patients would
not recognize as remission. Because most trials choose dif-
ferent endpoints, let alone different activity indices, com-
paring the results of different trials is exceptionally
difficult and the conduct of systematic reviews is seriously
impeded.
The Disease Activity Index (DAI, or Mayo score) is one of
the most widely used of the activity indices in clinical tri-
als. The impact of different definitions of remission using
the DAI is illustrated by one large patient cohort. The
ASCEND studies included a total of 687 patients with
mild to moderately active ulcerative colitis, treated with
2.4 g or 4.8 g mesalazine [25,26]. Using these three differ-
ent definitions of remission, the remission rate varied
more than two-fold. When the DAI was 0, it was 22% (in
other words, 'complete remission'); when the DAI was ≤ 1
the remission rate was 28% (meaning no bleeding and
normal frequency, with at least a 1 point decrease in sig-
moidoscopy score), but when 'remission' meant a DAI ≤
2, it was 50% (meaning total score ≤ 2, with no individual
subscore >1) [26]. This last definition of 'remission' is that
used in the ACT trials of infliximab for ulcerative colitis
refractory to standard therapy [27]. This is an extraordi-
nary degree of variation; it is no wonder that doctors and
patients are confused by different activity indices of clini-
cal trials. When inter-observer variation in sigmoidoscopy
scoring is factored in, the confusion becomes still greater.
Inter-observer variation in sigmoidoscopy assessment
Inter-observer variation in sigmoidoscopy scoring is a cru-
cial issue for regulatory authorities, since registration
remission is based on just two components, sigmoidos-
copy score and rectal bleeding. Investigators should
expect variation between observers and expect that this
variation is greatest when subjective assessments are
made. What is required is that this variation is quantified.
Recognition of this variation in clinical trials, further-
more, should lead both to training of observers in agreed
standards and at least one additional observer when sub-
jective assessments that are pivotal in regulatory terms
(such as endoscopy) are being made. When an independ-
ent observer re-evaluated the sigmoidoscopy videos in a
recent therapeutic trial of 335 patients with active ulcera-
tive colitis, the observer disagreed with the investigators'
sigmoidoscopy score in 12–23% of cases [28]. The impact
on the remission rates of this variation in the sigmoidos-
copy score was a median difference of 19% (range -10 to
22%) for absolute clinical, registration and complete
remission. If results were then analysed according to the
independent observer's score, remission rates were
reduced in absolute terms by 10–16% for registration, but
by <3% for clinical or complete remission. It is not sur-
prising that registration remission rates were most
affected. The implications are substantial. Inter-observer
variation alone has the potential to make the difference
between a therapeutically significant outcome and no
response, and between licensed approval and no licence.
Correlation between clinical activity and endoscopic 
mucosal appearance
It has been widely assumed that the activity of ulcerative
colitis is related to the mucosal appearances seen at sig-
moidoscopy. The concept is reasonable, but confidence is
misplaced when sigmoidoscopic assessment is so subjec-
tive and clinical activity unvalidated [29]. When 222
observations of 10 symptoms and signs were compared
with the sigmoidoscopic appearance, only the distinction
between mucosa that bled spontaneously and that which
bled on light touch or scraping was clinically meaningful
in discriminating between moderate and severe disease
[5]. Another study examined inter-observer agreement in
the assessment of ulcerative colitis in 273 videotaped
colonoscopies performed by 46 different endoscopists
and then evaluated by two independent observers [30].
There was agreement on mucosal friability, spontaneous
bleeding and mucopurulent exudates, which broadly cor-
related with clinical disease activity and histological activ-
ity scores. However, it has to be recognised that
sigmoidoscopy contributes very little to complete remis-
Table 5: Definitions of remission in ulcerative colitis [40]
Characteristic
Stool frequency Rectal bleeding Sigmoidoscopy score
Clinical remission Normal Absent ---
Registration remission --- Absent Normal or only erythema
Complete remission Normal Absent Normal or only erythemaTrials 2007, 8:17 http://www.trialsjournal.com/content/8/1/17
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sion (which includes symptomatic and endoscopic remis-
sion), compared to patient-defined remission (normal
stool frequency, lack of urgency and bleeding) [19]. The
different descriptive terms illustrate the need for mini-
mum standard terminology for describing the mucosal
appearance at sigmoidoscopy.
Histology scores
Paradoxically the histological grading of ulcerative colitis
has been subjected to the closest scrutiny [31-37],
although histology is neither a criterion in any of the scor-
ing systems, nor considered essential for the conduct of
clinical trials by the FDA. Even so, eight separate scoring
systems have been described for ulcerative colitis [2],
although only three are widely used [[11,36] and [37]].
Inter-observer agreement has been assessed in a blinded
fashion for 19 features. The features that provided most
consistency (in distinguishing ulcerative colitis from
Crohn's disease) were diffuse crypt architectural irregular-
ity, general crypt epithelial polymorphs and reduced crypt
numbers [35]. Binary variables (implying a 'yes' or 'no'
answer, or ordered categorical variables) ensured the
greatest agreement, as it was for endoscopy. Practical
application of these variables was further tested between
specialist gastrointestinal histopathologists, general his-
topathologists and trainees. Specialist histopathologists
found location of neutrophils (in the lamina propria or
between epithelial cells), the occurrence of crypt destruc-
tion, and the presence of erosions or ulcers to be the most
consistent variables [36]. Once trained in identifying spe-
cific features, inter-observer variation between general his-
topathologists and trainees was similar (Kappa = 0.64 and
0.53 respectively). This implies that training is valuable,
because it can both reduce interobserver variation and
potentially reduce the need for specialist observers
Although histopathology of rectal biopsy specimens is not
currently a trial requirement, there is a strong case for
making it so. This is for reasons of diagnosis, safety and
validation. Clinical trials in ulcerative colitis are recruiting
centres in areas of the world (Eastern Europe, India, Rus-
sia, and South America) that are not widely recognised as
having a clinical or research background in ulcerative col-
itis. Histopathology can corroborate the diagnosis,
exclude infection (an important safety issue with biother-
apy) and provide a permanent record. Trial validity is
enhanced, because if a patient said to have active colitis
actually has normal histology, then the diagnosis is wrong
and the patient should not have been included in the trial.
Furthermore, as mucosal healing emerges as a trial end-
point [38], histology provides independent corrobora-
tion.
Unmet needs
There is consequently a pressing need to quantify inter-
observer variation in videoendoscopic assessment of
ulcerative colitis, and to study its relation to clinical symp-
toms and histopathology. The starting point should be to
define the criteria for disease remission in a way that US
and European drug regulatory authorities (FDA and
EMEA) will recognise. Assessment of the degree of change
in endoscopic score also needs to be quantified. Clinical
trials have, until now, depended on unmatched scores at
a single time point, rather than on paired assessments.
This is because making a permanent endoscopic record
has never been part of the procedure. Agreement on stand-
ard outcomes for clinical trials is fundamentally impor-
tant. Such agreement can only be achieved by common
consent among authorative bodies of experts (such as the
International Organisation of Inflammatory Bowel Dis-
ease, IOIBD, or the European Crohn's and Colitis Organ-
isation, ECCO), in conjunction with patient-perspectives.
Such standard outcomes then have to be validated
through clinical trials.
Apart from questions that matter to drug regulatory
authorities, there are key questions of clinical relevance,
which also affect the conduct and outcome measurement
of trials [Table 6]. For instance, How often is there endo-
scopic activity when there is clinical remission? How often
is the endoscopy normal when there is clinical disease
activity? How often is there endoscopic activity when
there is histological remission? and, How often is the
endoscopy normal when there is histological activity.
Potential solutions
To answer these questions demands a substantial resource
of information, but this too can be defined:
1. Videoendoscopy of patients with active ulcerative coli-
tis before and after treatment.
Table 6: Unmet needs for outcomes of trials in ulcerative colitis
Develop a consensus definition of remission
For each index of disease activity:
Quantify the inter-observer variation for disease activity
Quantify the inter-observer variation for the degree of change 
between paired videos
Evaluate the relation between endoscopic score and clinical 
symptoms
Evaluate the relation between endoscopic activity and histological 
activity
Develop a consensus on a standard set of outcomes of disease 
activity to collect and report
Develop a consensus on a standard set of outcomes of clinical 
relevance to patients to collect and report (e.g. time to steroid-free 
remission, cumulative time off work or normal activities, hospital 
admission, colectomy)
¾
¾
¾
¾
¾
¾
¾Trials 2007, 8:17 http://www.trialsjournal.com/content/8/1/17
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2. Standardisation of endoscopy preparation, procedure
and assessment of mucosal friability.
3. Contemporaneous clinical scores on stool frequency
and rectal bleeding.
4. Matching mucosal biopsies from pre-determined sites.
The process would necessitate a random selection of vid-
eoendoscopies to be scored according to pre-determined
criteria evolving from Table 2, by a group of acknowl-
edged authorities in endoscopic and clinical practice, so
that a kappa statistic with narrow confidence interval can
be calculated for each component. Pre- and post-treat-
ment videoendoscopies would be randomised to avoid
explicit pairing and allow consistency to be evaluated, as
well as the ability to determine the degree of change
between videos from the same individual. The group of
features with the least inter-observer variation would then
be available for a validated scoring system. This need not
be limited by the graded terms mild, moderate, or severe,
but could simply define features such as mucosal friabil-
ity, spontaneous bleeding or mucosal ulceration. Correla-
tion between endoscopic appearance, clinical features and
histology is then possible.
Such a resource exists as a consequence of a recent clinical
trial on ulcerative colitis. (EUDRACT no: 2004-004077-
29). There are 670 videoendoscopies available for review
(paired videos on each of 335 patients). These endoscop-
ies were performed by experienced endoscopists who
received specific training on the conduct of procedures for
the study, and this training was reinforced when the inde-
pendent observer disagreed with the investigator's sig-
moidoscopy score during the trial. The criteria for the
conduct of the procedure, including preparation, tech-
nique of eliciting mucosal friability, and biopsy sites were
pre-determined. Plans are in place to select videoendo-
scopies for analysis by a group of experts in endoscopy
and the clinical management of ulcerative colitis and scor-
ing them independently, to define a kappa statistic with
narrow confidence intervals. Endoscopic scores can then
be related to contemporaneous data on stool frequency,
rectal bleeding, and histopathology. Once such data are
available then it would be appropriate to develop a stand-
ard set of outcomes for randomised controlled trials in
ulcerative colitis.
Conclusion
In trials of ulcerative colitis the lack of validated activity
indices, the lack of an internationally agreed definition of
remission, and the failure to quantify inter-observer vari-
ation in sigmoidoscopy scoring has a major impact on
outcome that is largely unrecognised. This affects registra-
tion of new drugs and makes meaningful comparison
between clinical trials exceptionally difficult. There is now
an opportunity to address inter-observer variation in sig-
moidoscopy scoring and to relate results to clinical activ-
ity and histopathology scoring. This will help set
standards for clinical, endoscopic, and histopathological
data collection and interpretation for future clinical trials
in ulcerative colitis allowing comparison and combina-
tion of trial results as is the case in rheumatology. It will
facilitate the international training of endoscopists in the
appearance and description at endoscopy. Once estab-
lished it can be used to assist regulatory evaluation of
evolving therapies and in national audit. Separate, vali-
dated scoring systems for clinical activity, sigmoidoscopy,
histopathology and quality of life, rather than a compos-
ite index, appear fundamental to clinical trial design. The
ultimate goal is to reach a consensus on key outcomes that
would always be assessed and reported in clinical trials.
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